BioSpace News Archive

Wize Pharma , Inc. (OTCQB: WIZP), a clinical-stage biopharmaceutical company focused on the treatment of ophthalmic disorders, today announced it has completed treating patients in its Phase IV clinical tri

EG Group and the American Cancer Society have announced that their nationwide partnership to drive funding for life-saving programs and services provided by the American Cancer Society has generated $252,394 in charitable donations.

- Total 2020 Charitable Grants to Date Approach $17 Million - - Lifetime Giving Approaches $112 Million -

May 7, 2020 13:00 UTC FDA-approved option for adult and pediatric patients available in 15 mM per 5 mL, 45 mM per 15 mL and 150 mM per 50 mL presentations LAKE ZURICH, Ill.--( BUSINESS WIRE )-- Fresenius Kabi announced today the immediate availability in the United States of Potassium Phosphates Injection, USP in the following presentations: 15 mM per 5 mL, 45 mM per 15 mL and 150 mM per 50 mL. This press release features multimedia. View the full release here: https://ww

Errant Gene Therapeutics (“EGT”) announces, that on April 30, 2020, the New York Supreme Court, First Department, Appellate Division unanimously affirmed rulings in EGT’s favor to proceed with fraud, unfair competition, and breach of contract claims in a trial scheduled October 29th, 2020 against Bluebird Bio and Sloan Kettering Institute for Cancer Research (SKI). EGT is represented by Ken Sussmane of McCue Sussmane Zapfel &

Vanderbilt University Medical Center and the biotech company IDBiologics, Inc., have joined forces to develop novel monoclonal antibody medicines that could potentially treat COVID-19 or prevent infection from the causative virus called SARS-CoV-2.

MIM Software Inc., a leading global provider of medical imaging software, announced today that DocPanel has selected MIM Software’s Nuclear Medicine platform to strengthen its Oncological Imaging capability.

Halozyme Therapeutics, Inc., will participate in the Bank of America Securities 2020 Healthcare Conference.

Genelux Corporation, a privately-held, clinical-stage immunotherapy company, today announced the outcome of a Type C meeting with the U.S. Food and Drug Administration (FDA) held on M

Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing novel cell therapies for unmet medical needs, annou